AlphAIalphai — Financial news for AI agents
minichart.com.sgAUG 202 min read

Viemed Healthcare Announces New Share Repurchase Program of Up to 5% of Shares Outstanding – Minichart

Viemed Healthcare reported Q2 2026 revenue of $78.1M (up 24% Y-o-Y) and Adjusted EBITDA of $13.7M. The company announced a new share repurchase program for up to 5% of outstanding shares, following a strong first half with 680,802 shares repurchased. Full-year 2026 guidance is $314M-$320M in revenue and $64M-$68M in Adjusted EBITDA. The company has a strong balance sheet with $10.7M in cash and no net debt as of June 30, 2026.

Original reporting
minichart.com.sg
Published Aug 20, 2026, 10:28 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 22, 2026, 12:13 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Viemed Healthcare Announces New Share Repurchase Program of Up to 5% of Shares Outstanding – Minichart — source image
Source · minichart.com.sg
Decision brief

The 30-second read

Med
01

Why it matters

The new guidance and repurchase program suggest stronger operational performance and confidence from management, likely influencing investor sentiment.

02

Market read

First‑report of FY2026 guidance and a 5% share buyback program, offering actionable insight for traders.

03

What to watch

Cash balance is modest ($10.7M) and future funding may depend on credit facilities.

Relevance 7/10Novelty 7/10Timing: post‑earnings August 2026

Background

Viemed Healthcare is a US‑listed provider of sleep and ventilator therapy services.

Market effects

Sector

Positive for the healthcare services sector as Viemed's growth may lift peers.

Regional

Limited to US small‑cap healthcare space.

Global

Minimal global impact.

Counterpoint

What could challenge this read

Buyback may be a short‑term price support that could fade if growth slows.

Key entities

  • Company
    Viemed Healthcare Inc.

    Provider of sleep therapy and ventilator services, ticker VIEM.

Read at source← All news

Related articles

AUG 11
$VMDMedAI 8/10

Viemed (VMD) Q2 2026 Earnings Call Transcript

Viemed Healthcare (VMD) reported Q2 2026 revenue of $78.1M, up 24% year over year, with ventilator patient counts reaching 12,635. Adjusted EBITDA was $13.7M (17.6% margin) and net income was $2.8M. Full-year 2026 revenue guidance was raised to $314M-$320M and adjusted EBITDA to $64M-$68M.

fool.com6 min
AUG 6
$VMDMedAI 8/10

Viemed Healthcare Q2 Earnings Call Highlights

Viemed Healthcare (NASDAQ:VMD) reported Q2 updates on home respiratory and sleep therapies. Management cited improved ventilator patient growth and said PAP setups rose, with sleep patients up about 5% sequentially and 44% YoY. Equipment sales nearly doubled to $19M. Gross profit was $45M (57.7% margin). Full-year net revenue guidance raised to $314M-$320M and adjusted EBITDA to $64M-$68M.

yahoo.com6 min
AUG 3
$VMDHigh

VIEMED HEALTHCARE, INC. (VMD): Results of Operations and Financial Condition

VIEMED HEALTHCARE, INC. (VMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. VIEMED HEALTHCARE ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS Lafayette, Louisiana (August 3, 2026) Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national provider of technology-enabled, home-based healthcare solutions and chronic disease management, ann

SEC EDGAR 8-K6 min
AUG 28
$HIMSHighAI 8/10

Hims & Hers (HIMS) CEO Says the FTC Doesn’t Understand His Own Company

Hims & Hers (HIMS) CEO Andrew Dudum defended the company against an FTC lawsuit, citing its revenue growth and subscriber base. Q2 revenue rose 40% YoY to $753M, with a full-year forecast of $3.1B-$3.3B. However, margins fell to 64% from 76%, and free cash flow was negative $68M, raising concerns about profitability and legal risks.

yahoo.com2 min